Clinical Trial

A Study in Healthy Men to Test How Well Different Doses of BI 3821001 Are Tolerated

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The main objectives of this trial are to investigate safety, tolerability and pharmacokinetics (PK) of BI 3821001 in healthy male trial participants.
Protocol Amendment History 1 change
critical Recruitment opened 2026-05-01
Trial Details
NCT Number NCT07526194
Lead Sponsor Boehringer Ingelheim
Conditions Healthy
Enrollment 72 participants
Start Date 2026-04-22
Primary Completion 2026-10-02 (estimated)
Study Completion 2026-10-02 (estimated)
Updated on ClinicalTrials.gov 2026-04-30